Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial

Minimal residual disease (MRD) by multiparameter flow cytometry (MFC) is the most effective tool to define a deep response in multiple myeloma (MM). We conducted an MRD correlative study of the EMN02/HO95 MM phase III trial in newly diagnosed MM patients achieving a suspected complete response befor...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliva, Stefania, Bruinink, Davine Hofste op, Rihova, Lucie, D’Agostino, Mattia, Pantani, Lucia, Capra, Andrea, van der Holt, Bronno, Troia, Rossella, Petrucci, Maria Teresa, Villanova, Tania, Vsianska, Pavla, Jugooa, Romana, Brandt-Hagens, Claudia, Gilestro, Milena, Offidani, Massimo, Ribolla, Rossella, Galli, Monica, Hajek, Roman, Gay, Francesca, Cavo, Michele, Omedé, Paola, van der Velden, Vincent H. J., Boccadoro, Mario, Sonneveld, Pieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175611/
https://www.ncbi.nlm.nih.gov/pubmed/34083504
http://dx.doi.org/10.1038/s41408-021-00498-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175611/
https://www.ncbi.nlm.nih.gov/pubmed/34083504
http://dx.doi.org/10.1038/s41408-021-00498-0

Ejemplares similares